Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 49

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 49
---
 the shares subject to the award vesting on the first, second and third anniversaries of March 4, 2025, such that each such award will vest in full on March 4, 2028, subject to the named executive officer’s continuous service with us as of each such vesting date.

February 2025 Cash Retention Bonuses

On February 23, 2025, the compensation committee and our board of directors, as applicable, approved cash retention bonuses to certain of our executive officers, including an additional $150,000 bonus payment payable to Dr. Zinda if his employment is terminated involuntarily. This cash retention bonus is payable on Dr. Zinda’s mutually agreed-upon separation date.

Promotion of Steve Forte to Chief Executive Officer in addition to Current Role as Chief Financial Officer

On March 31, 2025, the board appointed Steve Forte to serve as the Company’s President and Chief Executive Officer in addition to his current role as the Company’s Chief Financial Officer, effective as of April 11, 2025. In connection with his promotion to President and Chief Executive Officer, Mr. Forte and the Company entered into an amended employment agreement, dated March 31, 2025 (the “Amended Forte Employment Agreement”). Under the Amended Forte Employment Agreement, Mr. Forte will receive an annual base salary of $615,000, which is subject to redetermination annually by the compensation committee, and he is eligible to earn annual incentive compensation of up to 55% of his base salary. Mr. Forte was granted a stock option award to purchase 500,000 of the Company’s common shares at an exercise price of $1.07 per share. Additionally, Mr. Forte was entitled to receive reimbursement for certain legal fees in connection with entering into the Amended Forte Employment Agreement.**

<div align='center'>35</div>

The Amended Forte Employment Agreement provides that, in the event that Mr. Forte’s employment is terminated by the Company without “cause” and not due to death or “disability” or the executive resigns for “good reason,” in each case, not in connection with a “change in control” (each term as defined in the 2020 Plan), then he shall be entitled to (1) cash severance equal to twelve months of base salary, paid in twelve equal monthly instalments; (2) continued participation in the Company’s group insurance plans and employee benefits for